Search Results for: 19

Theriva Biologics anuncia la presentación de los datos de seguridad de uso y farmacocinética de la cohorte 1 del ensayo clínico de fase 1b/2a de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas

February 16, 2023 12:05 ET – Datos presentados en los Tandem Meetings 2023: Reuniones sobre trasplantes y terapias celulares de la ASTCT y el CIBMTR – – Los análisis de los pacientes que recibieron meropenem sugieren que SYN-004 se tolera bien con HCT y no se observó en las muestras de sangre de la mayoría […]

Theriva Biologics anuncia la presentación de los datos de seguridad de uso y farmacocinética de la cohorte 1 del ensayo clínico de fase 1b/2a de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas Read More »

Contact

Want to learn more? We’d love to hear from you. US Headquarters 9605 Medical Center Dr. Suite 270 Rockville, MD 20850 European Office Theriva™ Biologics SL Carrer Torrent de Can Ninou, naus 5-6 08150 – Parets del Vallès (Barcelona) Spain Email info@therivabio.com

Contact Read More »

Careers

WORK AT THERIVA™ As we grow, we continue to seek talented and driven scientists, marketers, analysts, and engineers who share in our mission. We are a collaborative, generous, and committed team that is devoted to leveraging the unique perspectives of every team member in our efforts to develop first-in-class cancer therapies. While there are no

Careers Read More »

Our Pipeline

OVERVIEW Theriva™ Biologics’ oncolytic viruses have the potential to treat a broad range of difficult-to-treat tumor types and may be combined with a variety of cancer therapies. In the VIRAGE Phase 2b clinical trial in patients with PDAC, VCN-01 (zabilugene almadenorepvec) combined withstandard-of care (SoC) chemotherapy gemcitabine/nab-paclitaxel improved outcomes compared to SoC chemotherapyalone. VCN-01 has

Our Pipeline Read More »

About Us

Overview Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. Ramon Alemany, recognized world-wide as a key opinion leader in adenovirus technologies, and are designed to enable systemic delivery and have the

About Us Read More »

Theriva™ Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

January 17, 2023 08:00 ET -Initiation of Phase 2b trial follows clearance from the US Food and Drug Administration (FDA) and Spanish Agency for Medicines and Health Products (AEMPS)- -The first patient was dosed in Spain; trial expected to enroll 92 adults at sites across the US, Spain, and Germany- ROCKVILLE, Md., Jan. 17, 2023

Theriva™ Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma Read More »

Theriva™ Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference

January 17, 2023 16:05 ET ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in one-on-one

Theriva™ Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference Read More »

Theriva™ Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

January 09, 2023 08:00 ET -Clinical trial is being conducted at St. James’s University Hospital, United Kingdom, in collaboration with the University of Leeds- ROCKVILLE, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas

Theriva™ Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors Read More »

Theriva™ Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results

November 10, 2022 16:45 ET –Reported encouraging clinical data supporting the differentiated mode-of action of Theriva’s novel oncolytic adenovirus (OV) platform– –Received clearance from the Federal Drug Administration (FDA) and Spanish Competent Authority (AEMPS) for the planned Phase 2 clinical trial of systemically administered VCN-01 in Pancreatic Ductal Adenocarcinoma (PDAC) patients– –Reported positive safety and

Theriva™ Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results Read More »